ABN: 89 609 406 911



22 November 2023

Change of Auditor

In accordance with ASX Listing Rule 3.16.3, **Melodiol Global Health Limited (ASX:ME1) ('Melodiol' or 'the Company')** advises that the Company has received approval from the Australian Securities and Investments Commission ("ASIC") to change its auditor.

Accordingly, the Company has now accepted the resignation of BDO Audit (WA) Pty Ltd ("BDO") and the consent of Crowe Audit Australia ("Crowe") to its appointment as Melodiol's auditor.

The decision to change auditors was made following a review by the Board of the Company's external audit arrangements in accordance with the Company's Corporate Governance Plan.

In accordance with section 327C of the Corporations Act 2001, a resolution will be placed at the Company's next Annual General Meeting to ratify the appointment of Crowe as the Company's auditor.

The Board of Directors would like to take this opportunity to thank BDO for their past assistance and professional services to the Company.

Authority and Contact Details

This announcement has been authorised for release by the Disclosure Committee of Melodiol Global Health Limited.

For further information, please contact:

Investor Enquiries

Melodiol Global Health Limited E: info@cresopharma.com

About Melodiol

Melodiol Global Health Limited (ASX:ME1) brings the best of cannabis and other plant-based products to better the lives of people and animals. Melodiol strives for the highest quality in its products. It develops cannabis, hemp-derived and other plant based therapeutic, nutraceutical, and lifestyle products with wide consumer reach.

To learn more please visit: https://melodiolglobalhealth.com/

Melodiol offices:

Australia: Suite 5 CPC, 145 Stirling Hwy, Nedlands, WA, 6009

Canada: 59 Payzant Drive, Windsor, Nova Scotia, BON 2TO and 50 Ivey Ln, Windsor, Nova Scotia, BON 2TO

ABN: 89 609 406 911



Forward Looking statements

This announcement contains forward-looking statements with respect to Melodiol and its respective operations, strategy, investments, financial performance and condition.

These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Melodiol could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Melodiol and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Melodiol has no obligation to up-date such statements, except to the extent required by applicable laws.